
Secretome Therapeutics Doses First Patient in Phase 1 Trial for Heart Failure Cell Therapy STM-01
Secretome Therapeutics has dosed the first patient in a phase 1 clinical trial (NCT06560762) evaluating STM-01, an investigational allogeneic neonatal cardiac progenitor cell (nCPC)-derived cell therapy, for the treatment of heart failure with preserved …